BridgeBio Announces Clinical Collaboration with Amgen to Stu

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

Related Keywords

China , Frank Mccormick , Amgen , Anderson Cancer Center Therapeutics Discovery , I Bridgebio Pharma Inc , Amgen Inc , University Of Texas , Bristol Myers Squibb , Nasdaq , Bridgebio Announces Clinical Collaboration , Potentially Best In Class , Advanced Solid Tumors , United Statesi January , Bridgebio Pharma , Anderson Cancer Center , Therapeutics Discovery , Small Molecule , New Chemical Entity , Ice , Chemistry , Mural , Inhaled , Drug Delivery , Depot , Flow Release ,